MedTrace Logo

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

NCT03211065 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-04-19

No results posted yet for this study

Summary

To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.

Conditions

  • Secondary Immune Deficiency

Interventions

DRUG

20% subcutaneous immunoglobulin

Subcutaneous Immunoglobulin

Sponsors & Collaborators

  • Rochester General Hospital

    lead OTHER

Principal Investigators

  • S Shahzad Mustafa, MD · Rochester Regional Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-21
Primary Completion
2019-11-01
Completion
2019-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03211065 on ClinicalTrials.gov